Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1944-1947

  Chandler, Paulette D ^a,b   Giovannucci, Edward L ^b,c,d   Scott, Jamil B ^d   Bennett, Gary G ^f   Ng, Kimmie ^b,e   Chan, Andrew T ^b,g   Hollis, Bruce W ^h   Emmons, Karen M ^b,e   Fuchs, Charles S ^b,e   Drake, Bettina F ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f DUKE UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; VITAMIN D;

ADULT; ARTICLE; BLACK PERSON; CANCER PREVENTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AFRICAN AMERICAN; DIET SUPPLEMENTATION; ETHNOLOGY; METABOLISM; MIDDLE AGED; RISK FACTOR; VITAMIN D DEFICIENCY;

ADULT; AFRICAN AMERICANS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84907167034     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0522     Document Type: Article

References (15)

1. Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 2009; 19: 96-102.
2. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035-9.
3. Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A, et al. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 2003; 9: 4077-83.
4. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitaminD(Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005; 51: 32-6.
5. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 2005; 11: 8680-5.
6. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25: 669-74.
7. Feldman D, Skowronski RJ, Peehl DM. Vitamin D and prostate cancer. Adv Exp Med Biol 1995; 375: 53-63.
8. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating retinol, vitamin E, and 1, 25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control 2012; 23: 1865-73.
9. Gilbert R, Metcalfe C, Fraser WD, Lewis S, Donovan J, Hamdy F, et al. Associations of circulating 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Eur J Cancer Prev 2013; 22: 121-5.
10. Tokar EJ, Webber MM. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis 2005; 22: 265-73.
11. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 2012; 97: 2315-24.
12. Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab 2013; 98: 1498-507.
13. Karlsson S, Olausson J, Lundh D, Sogard P, Mandal A, HolmströmKO, et al. Vitamin D and prostate cancer: the role of membrane initiated signaling pathways in prostate cancer progression. J Steroid Biochem Mol Biol 2010; 121: 413-6.
14. Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, Nadler RB, et al. Vitamin d deficiency predicts prostate biopsy outcomes. Clin Cancer Res 2014; 20: 2289-99.
15. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol 2013; 136: 233-7.